Fresh disappointment for Innate’s Astra lifeline
With Lumoxiti confirmed as commercially unviable monalizumab fails its phase 3 trial in head and neck cancer.
Key data catalysts for the industry’s small players
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Arcus’s near dream scenario
Gilead opts in at long last, and that’s more than many might have been expecting.
Esmo 2021 – Astra coasts towards a new lung cancer combo
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Upcoming events – key tests approach for Kadmon and Surface
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
